IQVIA Holdings Inc. (IQV) PEG Ratio: 6.34
Is IQVIA Holdings Inc.’s PEG ratio high or low?
IQVIA Holdings Inc.'s PEG ratio of 6.34 is 64% above its 5-year average of 3.87, around the middle of its 5-year range (0.23–10.65).
25.37% below its 12-month average of 8.50.
IQV PEG Ratio Chart
IQV Average PEG Ratio Chart
IQV Current vs Average PEG Ratio Chart
IQV PEG Ratio Metrics
PEG RATIO
6.34
PEG RATIO AVG TTM
8.50
PEG RATIO AVG 3Y
5.12
PEG RATIO AVG 5Y
3.87
PEG RATIO AVG 10Y
3.11
PEG RATIO AVG 15Y
2.42
PEG RATIO AVG 20Y
2.42
CURRENT VS TTM AVG
-25.37%
CURRENT VS 3Y AVG
+23.95%
CURRENT VS 5Y AVG
+63.97%
CURRENT VS 10Y AVG
+104.02%
CURRENT VS 15Y AVG
+162.38%
CURRENT VS 20Y AVG
+162.38%
IQV Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.22B | 6.34 | 8.50 | 5.12 | 3.87 |
| Biogen Inc. (BIIB) | $29.52B | N/A | 0.34 | 0.24 | 0.23 |
| Centene Corporation (CNC) | $31.37B | N/A | 0.18 | 0.16 | 0.16 |
| Medline Inc. (MDLN) | $31.40B | N/A | 0.07 | 0.07 | 0.07 |
| DexCom, Inc. (DXCM) | $29.04B | 0.66 | 19.99 | 10.91 | 8.76 |
| Zoetis Inc. (ZTS) | $34.13B | 2.04 | 2.96 | 3.83 | 3.78 |
| Veeva Systems Inc. (VEEV) | $26.31B | 1.42 | 1.47 | 5.64 | 5.88 |
| Agilent Technologies, Inc. (A) | $36.21B | 9.41 | 7.52 | 13.88 | 11.21 |
| Waters Corporation (WAT) | $23.21B | 75.62 | 75.62 | 40.78 | 27.51 |
| United Therapeutics Corporation (UTHR) | $23.15B | 1.16 | 0.84 | 0.59 | 0.59 |
Growth-Adjusted Valuation
PEG Ratio
6.34
P/E Ratio
22.4
IQVIA Holdings Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. PEG Ratio FAQ
- What is the PEG ratio for IQVIA Holdings Inc. (IQV)?
- The PEG ratio for IQV stock is 6.34.
- Is IQVIA Holdings Inc.'s PEG ratio high or low?
- IQVIA Holdings Inc.'s PEG ratio of 6.34 is 64% above its 5-year average of 3.87, around the middle of its 5-year range (0.23–10.65).
- What is the TTM average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average PEG ratio for IQV stock is 8.50.
- What is the 3Y average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average PEG ratio for IQV stock is 5.12.
- What is the 5Y average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average PEG ratio for IQV stock is 3.87.
- What is the 10Y average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average PEG ratio for IQV stock is 3.11.
- What is the 15Y average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The 15Y average PEG ratio for IQV stock is 2.42.
- What is the 20Y average PEG ratio for IQVIA Holdings Inc. (IQV)?
- The 20Y average PEG ratio for IQV stock is 2.42.
IQVIA Holdings Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 6.34 |
| 2024-12-31 | 10.65 |
| 2023-12-31 | 1.16 |
| 2022-12-31 | 2.31 |
| 2021-12-31 | 0.23 |
| 2020-12-31 | 2.51 |
| 2017-12-31 | 0.02 |
| 2015-12-31 | 1.64 |
| 2014-12-31 | 0.41 |
| 2013-12-31 | 0.88 |
| 2011-12-31 | 0.43 |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib